Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck to Eliminate Nearly 500 Jobs in Early 2020 Due to Shifting R&D Focus

Merck will slash about 500 jobs in early 2020 at two Montgomery County, Pa., facilities as well as in some other states, Pennsylvania’s Morning Call reported.

Read More »

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.

Read More »

Breast cancer drug gets FDA priority review

The U.S. drug regulator will give a speedy review to AstraZeneca Plc’s experimental breast cancer treatment trastuzumab deruxtecan.

Read More »

New System Hunts Down Cancer Cells that Hide from Immunotherapies

Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.

Read More »

J&J’s Xarelto Approved for 8th Indication by U.S. FDA

The U.S. FDA approved Janssen’s Xarelto (rivaroxaban) for preventing blood clots in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.

Read More »

Humira, Rituxan top list of U.S. drugs with biggest price increases: report

AbbVie Inc.’s rheumatoid arthritis drug Humira and Roche Holding AG’s cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report showed.

Read More »

Keytruda Set to Become World’s Top-Selling Drug, Forecast Shows

While the top-selling prescription drug Humira is on the decline internationally due to increased competition and expiring patents, another medicine is on track to eventually take hold of the world’s No. 1 rank: Merck’s Keytruda.

Read More »

AstraZeneca strengthens Lynparza push with prostate cancer data

AstraZeneca presented results for a late-stage clinical trial of Lynparza against prostate cancer, which the company hopes could lead to wider regulatory approval for more forms of the disease.

Read More »

Novartis says Kisqali boosts survival in breast cancer patients

Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.

Read More »

Positive Data Reported for Merck’s Keytruda Plus Chemo Combo as Neoadjuvant Therapy in Early-Stage TNBC

Merck announced results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial in patients with early-stage triple-negative breast cancer (TNBC).

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom